Topics

Companies Related to "Ortho markets predictive heart failure hospitalisation test" [Most Relevant Company Matches] RSS

13:36 EST 25th February 2020 | BioPortfolio

Here are the most relevant search results for "Ortho markets predictive heart failure hospitalisation test" found in our extensive corporate database of over 50,000 company records.

Showing "Ortho markets predictive heart failure hospitalisation test" Companies 1–25 of 4,400+

Extremely Relevant

Sunshine Heart

Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. Over five million people in the United States have heart failure and it results in over 300,000 deaths each year. Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.


The Heart Failure Society of America

Heart failure is a progressive condition in which the heart muscle becomes abnormal after damage from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in th...

Ancora Heart Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...


Ancora Heart, Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...

Heart Failure Society of America, Inc.

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The Mission of HFSA is to: Promote research related to all aspects of heart failure and to provide a forum for presentation of ba...

Relevant

ARCA biopharma, Inc.

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that i...

Texas Heart Institute

The Texas Heart Institute (www.texasheart.org), founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education and improved patient care. Together with its clinical partner, St. ...

SynCardia Systems, LLC

SynCardia Systems, LLC (www.syncardia.com) in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a brid...

Terumo Heart Inc.

More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transpla...

IPS HEART

IPS HEART is a privately-held biopharmaceutical company dedicated to addressing heart attack, heart failure and duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells and heart disease. IPS HEART is a resident at Johnson & Johnson Innovation, JLABS at TMC in the T...

VIRalliance

VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology.VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment.PHENOSCRIPT™ is the first of these tests to be made available to the public. PHENOSCRIPT™ is a novel and rapid HIV phen...

3F Therapeutics, Inc

3F Therapeutics, Inc. was formed in late 1998 to develop, manufacture, and market innovative cardiovascular devices for patients with currently unmet clinical needs. The Company’s products are intended to significantly improve upon the performance of heart valves presently in the market and to address the resultant complications of patients with congestive heart failure. At present, over 260,000...

Celladon Corporation

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium ...

DC Devices, Inc.

DC Devices, Inc. is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). The InterAtrial Shunt Device (IASD™) S...

Ortho Biotech, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients'...

VADovations, Inc.

Revolutionizing cardiac support technology and the treatment of heart failure, VADovations is developing ultra-miniaturized blood pumps designed for minimally invasive and percutaneous, endovascular deployment while addressing the total spectrum of advanced heart failure therapy with the best possible quality and cost-effectiveness. Contact: john.frick@vadovations.com; Visit https://vadovations.c...

Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients'...

CardioKine, Inc.

CardioKine is a specialty pharmaceutical company developing innovative compounds for the treatment and prevention of heart failure and related cardiovascular indications.Heart failure is one of the world’s fastest growing diseases, impacting all segments of society. It occurs when the heart becomes too weak to pump blood, leading to accumulation of fluids, shortness of breath and premature death...

Celladon Corp.

Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company's products target calcium cycling and contractility deficit in heart muscle cells. In addition to MYDICAR®, Celladon is developing traditional small molecule activato...

Sunshine Heart, Inc.

Sunshine Heart (ASX:SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-...

Ortho Women's Health & Urology(TM)

Ortho Women's Health & Urology(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a leader in the fields of women's health and urology, celebrating more than 75 years of partnering with women. Ortho Women's Health & Urology(TM) is committed to helping people live healthier lives and to meeting the needs of healthcare professionals and patients with products such as ORTHO TRI-CYCLEN(R)...

Ortho Biotech Incorporated

Ortho Biotech Inc. is a member of the Johnson & Johnson family of companies. As a company engaged in the business of innovative research, Ortho Biotech is pleased to share with professionals and patients its resources on the subject of anemia associated with HIV therapy.

Ortho-McNeil Neurologics

Headquartered in Titusville, NJ, Ortho-McNeil Neurologics(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, focuses exclusively on providing solutions that improve neurological health. The company has products for Alzheimer's disease, epilepsy, and acute and preventive migraine treatment. Ortho-McNeil Neurologics(R), in conjunction with internal and external research partners, continues t...

ORQIS Medical Corporation

ORQIS Medical Corporation is a privately held, medical device company developing its discovery of a novel approach to treat the underlying mechanisms responsible for congestive heart failure. ORQIS Medical discovered that continuous aortic flow augmentation (CAFA), blood flow augmentation specifically in the descending aorta, may correct abnormal circulatory conditions associated with heart failur...

CircuLite®, Inc.

CircuLite is developing disruptive solutions to improve the treatment of chronic heart failure. The Company’s minimally invasive circulatory support systems are intended to work in conjunction with the heart to enhance clinical outcomes and improve quality of life for patients and their families. Synergy®, currently in a CE Mark clinical trial, fea...


More From BioPortfolio on "Ortho markets predictive heart failure hospitalisation test"

Quick Search

Corporate Database Quicklinks